391 related articles for article (PubMed ID: 15451670)
1. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.
Reid TS; Terry KL; Casey PJ; Beese LS
J Mol Biol; 2004 Oct; 343(2):417-33. PubMed ID: 15451670
[TBL] [Abstract][Full Text] [Related]
2. Conversion of protein farnesyltransferase to a geranylgeranyltransferase.
Terry KL; Casey PJ; Beese LS
Biochemistry; 2006 Aug; 45(32):9746-55. PubMed ID: 16893176
[TBL] [Abstract][Full Text] [Related]
3. Targeted reengineering of protein geranylgeranyltransferase type I selectivity functionally implicates active-site residues in protein-substrate recognition.
Gangopadhyay SA; Losito EL; Hougland JL
Biochemistry; 2014 Jan; 53(2):434-46. PubMed ID: 24344934
[TBL] [Abstract][Full Text] [Related]
4. Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate.
Long SB; Casey PJ; Beese LS
Biochemistry; 1998 Jul; 37(27):9612-8. PubMed ID: 9657673
[TBL] [Abstract][Full Text] [Related]
5. Peptide specificity of protein prenyltransferases is determined mainly by reactivity rather than binding affinity.
Hartman HL; Hicks KA; Fierke CA
Biochemistry; 2005 Nov; 44(46):15314-24. PubMed ID: 16285735
[TBL] [Abstract][Full Text] [Related]
6. Selective modification of CaaX peptides with ortho-substituted anilinogeranyl lipids by protein farnesyl transferase: competitive substrates and potent inhibitors from a library of farnesyl diphosphate analogues.
Troutman JM; Subramanian T; Andres DA; Spielmann HP
Biochemistry; 2007 Oct; 46(40):11310-21. PubMed ID: 17854205
[TBL] [Abstract][Full Text] [Related]
7. Reaction path of protein farnesyltransferase at atomic resolution.
Long SB; Casey PJ; Beese LS
Nature; 2002 Oct; 419(6907):645-50. PubMed ID: 12374986
[TBL] [Abstract][Full Text] [Related]
8. Amino acid residues that define both the isoprenoid and CAAX preferences of the Saccharomyces cerevisiae protein farnesyltransferase. Creating the perfect farnesyltransferase.
Caplin BE; Ohya Y; Marshall MS
J Biol Chem; 1998 Apr; 273(16):9472-9. PubMed ID: 9545274
[TBL] [Abstract][Full Text] [Related]
9. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae.
Trueblood CE; Ohya Y; Rine J
Mol Cell Biol; 1993 Jul; 13(7):4260-75. PubMed ID: 8321228
[TBL] [Abstract][Full Text] [Related]
10. Farnesylation and proteolysis are sequential, but distinct steps in the CaaX box modification pathway.
Farh L; Mitchell DA; Deschenes RJ
Arch Biochem Biophys; 1995 Apr; 318(1):113-21. PubMed ID: 7726551
[TBL] [Abstract][Full Text] [Related]
11. Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase.
Yang W; Del Villar K; Urano J; Mitsuzawa H; Tamanoi F
J Cell Biochem Suppl; 1997; 27():12-9. PubMed ID: 9591188
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
Qian Y; Vogt A; Sebti SM; Hamilton AD
J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
[TBL] [Abstract][Full Text] [Related]
13. Role of the carboxyterminal residue in peptide binding to protein farnesyltransferase and protein geranylgeranyltransferase.
Roskoski R; Ritchie P
Arch Biochem Biophys; 1998 Aug; 356(2):167-76. PubMed ID: 9705207
[TBL] [Abstract][Full Text] [Related]
14. Sequence dependence of protein isoprenylation.
Moores SL; Schaber MD; Mosser SD; Rands E; O'Hara MB; Garsky VM; Marshall MS; Pompliano DL; Gibbs JB
J Biol Chem; 1991 Aug; 266(22):14603-10. PubMed ID: 1860864
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and structural studies with prenyl diphosphate analogues provide insights into isoprenoid recognition by protein farnesyl transferase.
Turek-Etienne TC; Strickland CL; Distefano MD
Biochemistry; 2003 Apr; 42(13):3716-24. PubMed ID: 12667062
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
[TBL] [Abstract][Full Text] [Related]
17. Module assembly for protein-surface recognition: geranylgeranyltransferase I bivalent inhibitors for simultaneous targeting of interior and exterior protein surfaces.
Machida S; Usuba K; Blaskovich MA; Yano A; Harada K; Sebti SM; Kato N; Ohkanda J
Chemistry; 2008; 14(5):1392-401. PubMed ID: 18200641
[TBL] [Abstract][Full Text] [Related]
18. The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures.
Long SB; Casey PJ; Beese LS
Structure; 2000 Feb; 8(2):209-22. PubMed ID: 10673434
[TBL] [Abstract][Full Text] [Related]
19. Upstream polybasic region in peptides enhances dual specificity for prenylation by both farnesyltransferase and geranylgeranyltransferase type I.
Hicks KA; Hartman HL; Fierke CA
Biochemistry; 2005 Nov; 44(46):15325-33. PubMed ID: 16285736
[TBL] [Abstract][Full Text] [Related]
20. Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes.
Reid TS; Long SB; Beese LS
Biochemistry; 2004 Jul; 43(28):9000-8. PubMed ID: 15248757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
